US angioplasty market braces for new stents
This article was originally published in Clinica
The $450 million US angioplasty market could change radically in the next two years. The approval of second-generation stents will eat into Cordis' 95% share of the stent market and companies that offer a broad range of angioplasty products will be the favourites with the big healthcare providers. Lehman Brothers analysts Amelia McDonald and Jonathan Foster project 20% annual growth in the stent market for each of the next three years.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.